A Phase 1 interventional study of Radiprodil and Carbamazepine in Healthy Adult Participants, sponsored by GRIN Therapeutics, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by GRIN Therapeutics, Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, open-label, 2-part study in healthy adult participants to evaluate the pharmacokinetics and safety of radiprodil when coadministered with either the CYP3A4 inducer carbamazepine or the CYP3A4 inhibitor itraconazole. Up to 36 participants will be enrolled, with approximately 18 participants in Part A and 18 participants in Part B.
Part A will evaluate the effect of carbamazepine on the plasma pharmacokinetic profile of radiprodil. Participants will receive a single 30 mg oral dose of radiprodil under fed conditions, followed by multiple oral doses of carbamazepine, and then coadministration of radiprodil 30 mg with carbamazepine 300 mg.
Part B will evaluate the effect of itraconazole on the plasma pharmacokinetic profile of radiprodil. Participants will receive a single 15 mg oral dose of radiprodil under fed conditions, followed by multiple oral doses of itraconazole, and then coadministration of radiprodil 15 mg with itraconazole 200 mg.
GRIN Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of radiprodil 30 mg under fed conditions on Day 1. Carbamazepine will then be administered orally twice daily with food at escalating doses: 100 mg BID on Days 4 to 5, 200 mg BID on Days 6 to 7, and 300 mg BID on Days 8 to 15. On Day 16, radiprodil 30 mg will be coadministered with carbamazepine 300 mg under fed conditions. Carbamazepine 300 mg BID will continue on Days 17 to 18. Participants will be discharged on Day 21 and attend a follow-up visit 30 days ± 2 days after the last carbamazepine dose.
Drug: Radiprodil · Drug: Carbamazepine
Participants will receive a single oral dose of radiprodil 15 mg under fed conditions on Day 1. Itraconazole 200 mg once daily will be administered orally with food on Days 4 to 8. On Day 9, radiprodil 15 mg will be coadministered with itraconazole 200 mg under fed conditions. Itraconazole 200 mg once daily will continue on Days 10 to 11. Participants will be discharged on Day 12 and attend a follow-up visit 30 days ± 2 days after the last itraconazole dose.
Drug: Radiprodil · Drug: Itraconazole (200 mg)
Radiprodil administered orally as a single dose of 30 mg in Part A or 15 mg in Part B under fed conditions.
Also known as: RGH-896, Radiprodil oral suspension
Carbamazepine administered orally twice daily at doses of 100 mg, 200 mg, and 300 mg in Part A to evaluate the effect of CYP3A4 induction on the pharmacokinetics of radiprodil.
Itraconazole administered orally at 200 mg once daily in Part B to evaluate the effect of CYP3A4 inhibition on the pharmacokinetics of radiprodil.
AUClast of Radiprodil - Part A
Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUClast) of radiprodil following administration of radiprodil alone on Day 1 and with carbamazepine on Day 16. The effect of carbamazepine will be assessed using the geometric mean ratio and 90% confidence interval.
Time frame: Part A: Day 1 through Day 19
AUCinf of Radiprodil - Part A
Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinf) of radiprodil following administration of radiprodil alone on Day 1 and with carbamazepine on Day 16. The effect of carbamazepine will be assessed using the geometric mean ratio and 90% confidence interval.
Time frame: Part A: Day 1 through Day 19
Cmax of Radiprodil - Part A
Maximum observed plasma concentration (Cmax) of radiprodil following administration of radiprodil alone on Day 1 and with carbamazepine on Day 16. The effect of carbamazepine will be assessed using the geometric mean ratio and 90% confidence interval.
Time frame: Part A: Day 1 through Day 19
AUClast of Radiprodil - Part B
Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUClast) of radiprodil following administration of radiprodil alone on Day 1 and with itraconazole on Day 9. The effect of itraconazole will be assessed using the geometric mean ratio and 90% confidence interval.
Time frame: Part B: Day 1 through Day 12
AUCinf of Radiprodil - Part B
Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinf) of radiprodil following administration of radiprodil alone on Day 1 and with itraconazole on Day 9. The effect of itraconazole will be assessed using the geometric mean ratio and 90% confidence interval.
Time frame: Part B: Day 1 through Day 12
Cmax of Radiprodil - Part B
Maximum observed plasma concentration (Cmax) of radiprodil following administration of radiprodil alone on Day 1 and with itraconazole on Day 9. The effect of itraconazole will be assessed using the geometric mean ratio and 90% confidence interval.
Time frame: Part B: Day 1 through Day 12
AUClast of Carbamazepine - Part A
Area under the plasma concentration-time curve from time zero to the last quantifiable concentration of carbamazepine following administration alone and in combination with radiprodil.
Time frame: Part A: Day 16 (up to 12 hours post-dose)
AUCtau of Carbamazepine - Part A
Area under the plasma concentration-time curve over the 12-hour dosing interval (AUCtau) of carbamazepine following coadministration with radiprodil.
Time frame: Part A: Day 16 (up to 12 hours post-dose)
Cmax of Carbamazepine - Part A
Maximum observed plasma concentration (Cmax) of carbamazepine following coadministration with radiprodil.
Time frame: Part A: Day 16 (up to 12 hours post-dose)
Tmax of Carbamazepine - Part A
Time to reach maximum observed plasma concentration of carbamazepine following administration alone and in combination with radiprodil.
Time frame: Part A: Day 16 (up to 12 hours post-dose)
AUClast of Itraconazole - Part B
Area under the plasma concentration-time curve from time zero to the last quantifiable concentration of itraconazole following administration alone and in combination with radiprodil.
Time frame: Part B: Day 9 through Day 10 (up to 24 hours post-dose)
AUCtau of Itraconazole - Part B
Area under the plasma concentration-time curve over the dosing interval of itraconazole following administration alone and in combination with radiprodil.
Time frame: Part B: Day 9 through Day 10 (up to 24 hours post-dose)
Cmax of Itraconazole - Part B
Maximum observed plasma concentration of itraconazole following administration alone and in combination with radiprodil.
Time frame: Part B: Day 9 through Day 10 (up to 24 hours post-dose)
Tmax of Itraconazole - Part B
Time to reach maximum observed plasma concentration of itraconazole following administration alone and in combination with radiprodil.
Time frame: Part B: Day 9 through Day 10 (up to 24 hours post-dose)
Tmax of Radiprodil - Part A
Time to reach maximum observed plasma concentration of radiprodil. Assessed following administration of radiprodil alone and in combination with carbamazepine.
Time frame: Part A: Day 1 through Day 19
Terminal Elimination Half-Life (t½) of Radiprodil - Part A
Terminal elimination half-life of radiprodil, defined as the time required for plasma concentration to decrease by half during the terminal elimination phase. Assessed following administration of radiprodil alone and in combination with carbamazepine.
Time frame: Part A: Day 1 through Day 19
Apparent Total Body Clearance (CL/F) of Radiprodil - Part A
Apparent total body clearance of radiprodil following oral administration. Assessed following administration of radiprodil alone and in combination with carbamazepine.
Time frame: Part A: Day 1 through Day 19
Apparent Volume of Distribution (Vz/F) of Radiprodil - Part A
Apparent volume of distribution of radiprodil during the terminal elimination phase following oral administration. Assessed following administration of radiprodil alone and in combination with carbamazepine.
Time frame: Part A: Day 1 through Day 19
Tmax of Radiprodil - Part B
Time to reach maximum observed plasma concentration of radiprodil. Assessed following administration of radiprodil alone and in combination with itraconazole.
Time frame: Part B: Day 1 through Day 12
Terminal Elimination Half-Life (t½) of Radiprodil - Part B
Terminal elimination half-life of radiprodil, defined as the time required for plasma concentration to decrease by half during the terminal elimination phase. Assessed following administration of radiprodil alone and in combination with itraconazole.
Time frame: Part B: Day 1 through Day 12
Apparent Total Body Clearance (CL/F) of Radiprodil - Part B
Apparent total body clearance of radiprodil following oral administration. Assessed following administration of radiprodil alone and in combination with itraconazole.
Time frame: Part B: Day 1 through Day 12
Apparent Volume of Distribution (Vz/F) of Radiprodil - Part B
Apparent volume of distribution of radiprodil during the terminal elimination phase following oral administration. Assessed following administration of radiprodil alone and in combination with itraconazole.
Time frame: Part B: Day 1 through Day 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Number and percentage of participants with at least one treatment-emergent adverse event (TEAE), summarised by treatment period and overall for each study part. TEAEs are adverse events occurring or worsening after the first dose of study drug.
Time frame: From first dose of study drug through follow-up (up to approximately 90 days in Part A and 69 days in Part B)
Number of Participants With Serious Adverse Events (SAEs)
Number of participants experiencing at least one serious adverse event, summarised separately for each study part.
Time frame: From signing of informed consent through follow-up (up to approximately 90 days in Part A and 69 days in Part B)
Change From Baseline in Systolic Blood Pressure
Change from baseline in systolic blood pressure, measured in mmHg, summarised by scheduled assessment time point and treatment period within each study part.
Time frame: From baseline through follow-up
Change From Baseline in Diastolic Blood Pressure
Change from baseline in diastolic blood pressure, measured in mmHg, summarised by scheduled assessment time point and treatment period within each study part.
Time frame: From baseline through follow-up
Change From Baseline in Pulse Rate
Change from baseline in pulse rate, measured in beats per minute, summarised by scheduled assessment time point and treatment period within each study part.
Time frame: From baseline through follow-up
Change From Baseline in Body Temperature
Change from baseline in body temperature, measured in degrees Celsius, summarised by scheduled assessment time point and treatment period within each study part.
Time frame: From baseline through follow-up
Change From Baseline in Respiratory Rate
Change from baseline in respiratory rate, measured in breaths per minute, summarised by scheduled assessment time point and treatment period within each study part.
Time frame: From baseline through follow-up
Number of Participants With QTcF Interval Above 450 Milliseconds
Number of participants with a QT interval corrected using Fridericia's formula (QTcF) greater than 450 milliseconds during the study.
Time frame: From baseline through follow-up
Number of Participants With QTcF Interval Above 480 Milliseconds
Number of participants with a QTcF interval greater than 480 milliseconds during the study.
Time frame: From baseline through follow-up
Number of Participants With QTcF Interval Above 500 Milliseconds
Number of participants with a QTcF interval greater than 500 milliseconds during the study.
Time frame: From baseline through follow-up
Number of Participants With QTcF Increase From Baseline of at Least 30 Milliseconds
Number of participants with an increase in QTcF from baseline of at least 30 milliseconds during the study.
Time frame: From baseline through follow-up
Number of Participants With QTcF Increase From Baseline of at Least 60 Milliseconds
Number of participants with an increase in QTcF from baseline of at least 60 milliseconds during the study.
Time frame: From baseline through follow-up
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Oct 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carbamazepine · Itraconazole
GRIN Therapeutics, Inc.